Skip to main content
Medical information Clinical review pending

Transplant Testing

HLA Pretransplant Workup Sensitized Recipient Panel 3 Test

The HLA Pretransplant Workup Sensitized Recipient Panel 3 Test helps assess compatibility between potential organ donors and recipients awaiting kidney or liver transplants, especially those who are sensitized. This test identifies antibodies that could lead to rejection.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
12 mL (10 mL minimum) whole blood in 2 Yellow Top (ACD) tubes; 4 mL (2 mL minimum) whole blood in 1 Lavender Top (EDTA) tube.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the doctor's prescription on letterhead, photographs of both recipient and donor, and a completed Consent Form for HLA Typing for Solid Organ Transplant (Form 33) are provided with the sample.
Test priceKSh 46,098

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the HLA Pretransplant Workup Sensitized Recipient Panel 3 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients awaiting kidney or liver transplantation.
  • ✓Individuals considered 'sensitized' (e.g., history of previous transplants, blood transfusions, pregnancies).
  • ✓Patients with a history of organ rejection.
  • ✓Assessing compatibility between potential donor and recipient.
  • ✓Guiding donor selection to minimize rejection risk.
02

In plain language

What this test helps you understand

This test is used to identify antibodies in potential transplant recipients that could react against donor tissues, helping to predict the risk of rejection and guide donor selection for kidney or liver transplants.
The HLA Pretransplant Workup Sensitized Recipient Panel 3 Test is a crucial part of the process for individuals preparing for a kidney or liver transplant. It is particularly important for patients considered 'sensitized,' meaning they have developed antibodies against HLA antigens due to previous transplants, blood transfusions, or pregnancies.

This test helps determine the compatibility between a potential donor's tissue type and the recipient's immune system. By identifying specific antibodies in the recipient's blood that could react against the donor's tissues, the test helps predict the risk of organ rejection. This information is vital for healthcare providers to select the most suitable donor, increasing the chances of a successful transplant.

The test utilizes advanced laboratory techniques to analyze the recipient's HLA antibodies. Understanding the results allows medical teams to make informed decisions about donor matching and manage potential risks associated with the transplant.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the doctor's prescription on letterhead, photographs of both recipient and donor, and a completed Consent Form for HLA Typing for Solid Organ Transplant (Form 33) are provided with the sample.
Sample12 mL (10 mL minimum) whole blood in 2 Yellow Top (ACD) tubes; 4 mL (2 mL minimum) whole blood in 1 Lavender Top (EDTA) tube.
MethodologyComplement Dependent Cytotoxicity with DTT treatment and Reverse SSOP - Luminex.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test identifies known HLA antibodies. It may not detect all potential causes of rejection. Results must be interpreted in the context of the patient's overall clinical picture by a qualified healthcare professional.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

A 'sensitized' recipient is someone whose immune system has previously developed antibodies against HLA antigens, often due to past transplants, blood transfusions, or pregnancies. This can make finding a compatible donor more challenging.
This test helps identify antibodies that could cause the recipient's body to reject the transplanted organ. Finding the best possible match reduces the risk of rejection and improves transplant success.
A blood sample is required. Specific volumes and tube types (Yellow Top ACD and Lavender Top EDTA) are needed. Please refer to the specimen requirements section for details.
Turnaround time varies. Please contact the laboratory directly for the most current information.
No fasting is required for this blood test.
A doctor's prescription on letterhead, photographs of both the recipient and donor, and a completed Consent Form for HLA Typing for Solid Organ Transplant (Form 33) are required.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp